From: Types of second primary cancer influence overall survival in cutaneous melanoma
Gender | Age at diagnosis (years old) | No SPC | Interval from first melanoma diagnosis to SPC | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
< 1 year | 1–5 year | 6–10 year | > 10 year | ||||||||
N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | N | HR (95% CI) | ||
Second melanoma | |||||||||||
Males | < 60 | 1304 | Reference | 20 | 2.41 (1.54–3.77) | 36 | 2.81 (2.00–3.94) | 10 | 0.87 (0.47–1.63) | 13 | 0.63 (0.36–1.11) |
60–79 | 3189 | 2.96 (2.76–3.16) | 59 | 3.98 (3.12–5.07) | 72 | 4.39 (3.47–5.56) | 48 | 4.75 (3.64–6.19) | 27 | 4.76 (3.33–6.80) | |
≥80 | 1677 | 8.17 (7.53–8.86) | 30 | 7.57 (5.41–10.6) | 30 | 11.1 (7.90–15.6) | 8 | 7.16 (4.57–11.2) | |||
Females | < 60 | 840 | Reference | 6 | 1.37 (0.59–3.18) | 14 | 1.64 (0.94–2.87) | 3 | 0.42 (0.14–1.29) | 5 | 0.28 (0.12–0.68) |
60–79 | 2062 | 4.23 (3.89–4.59) | 24 | 5.09 (3.39–7.63) | 33 | 6.19 (4.34–8.84) | 17 | 5.92 (3.66–9.57) | 16 | 6.08 (3.85–9.60) | |
≥80 | 1964 | 14.3 (13.1–15.7) | 23 | 15.9 (10.6–23.9) | 25 | 17.2 (12.0–24.5) | 9 | 19.9 (11.1–35.8) | 2 | 22.4 (9.66–52.1) | |
Other SPC | |||||||||||
Males | < 60 | 1304 | Reference | 15 | 5.16 (2.95–9.02) | 59 | 3.71 (2.77–4.97) | 65 | 3.61 (2.79–4.67) | 100 | 2.90 (2.30–3.66) |
60–79 | 3189 | 2.96 (2.77–3.17) | 108 | 7.65 (6.21–9.43) | 443 | 7.20 (6.42–8.08) | 309 | 7.40 (6.52–8.39) | 201 | 8.18 (7.03–9.51) | |
≥80 | 1677 | 8.29 (7.65–8.98) | 57 | 13.5 (10.7–17.1) | 174 | 11.9 (10.2–13.9) | 44 | 14.2 (10.6–19.1) | 3 | 10.0 (2.80–35.9) | |
Females | < 60 | 840 | Reference | 15 | 4.89 (2.77–8.64) | 66 | 5.97 (4.5–7.91) | 65 | 4.56 (3.47–6.00) | 104 | 3.81 (3.04–4.77) |
60–79 | 2062 | 4.25 (3.91–4.61) | 51 | 13.0 (9.26–18.4) | 213 | 11.7 (9.9–13.7) | 181 | 11.9 (9.94–14.3) | 125 | 15.3 (12.3–19.1) | |
≥80 | 1964 | 14.5 (13.2–15.8) | 36 | 17.6 (12.2–25.3) | 136 | 22.5 (18.8–27.1) | 40 | 16.4 (11.8–23.0) | 8 | 17.4 (8.14–37.4) |